An interventional study of WGS Diagnostic Blood take for genetic diagnostic. and Hair collection in Rare Diseases and Genetic Predisposition to Disease, sponsored by University Hospital Tuebingen. Recruiting at 2 sites in Germany. Per ClinicalTrials.gov, last updated 2023-11-29.
Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The GENOME + project will enroll patients (n = ca. 100) and their healthy parents with unclear molecular cause of the disease, suspected genetic cause of the disease and previous detailed molecular analysis like Whole Exome Sequencing (WES) did not lead to the identification of the disease causing mechanism. As well healthy parents of those affected for trio analysis (exception of one parent is not available for the study).
In the GENOME+ study (monocentric, prospective, open-label diagnostic study), patients with molecularly undiagnosed diseases will diagnostically be analyzed by means of omics technologies or re-analyzed using existing datasets. The following questions will be leading the study:
Primary:
Secondary:
In addition, healthy parents of the subjects may be included in the study to perform parent-child (trio) analyses.
In addition, phenotype and omics data will be shared within the University Hospital Tübingen, Germany and with external collaborators to improve the diagnostic rate of the patients included in the study.
Storage of blood or tissue samples is not primary goal of this project, but may be necessary for further analyses.
592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.
This study's planned enrollment of 100 is above the median of 45 across 339 interventional studies indexed under Rare Diseases.
Browse Rare Diseases studies →University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. In addition, healthy parents of volunteers will be recruited if available to facilitate Trio studies. Study related procedures: Blood sampling, hair collection, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures, organoid cultivation).
Genetic: WGS Diagnostic Blood take for genetic diagnostic. · Genetic: Hair collection
Blood sampling, shot clinical characterization, WGS based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA Sequencing (RNA-seq).
Hair including root will be collected from the scalp (\~15-20) and transferred to cultivation medium for the organoid cultivation
Identification of the molecular causes of unclear rare diseases
Number of molecular causes
Time frame: Day 1
Diagnoses for patients with rare diseases
Number of diagnoses for patients with rare diseases
Time frame: Day 1
Molecular characterization of putative disease causes
Identify molecular characterization of the putative disease causes
Time frame: Day 1
Patients receiving appropriate therapy after successful diagnosis
Number of patients receiving appropriate therapy after successful diagnosis
Time frame: Day 1
Plan to share: Yes — The GENOME+ study will provide data in a pseudonymized manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools and matchmaking against other cohorts
Supporting information: Analytic code
Time frame: Data will become available after analysis and unlimited.
Access criteria: Authorized users within the participating organizations
No publications or documents are linked to this record.
Started Feb 2021 (actual). Primary completion is estimated for Jul 2024, 41 months after the start.
Of 36 interventional studies with no phase under Rare Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 41 months is above that.
Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Tuebingen →